Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes

Danilo Verge, Ximena López

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Type 2 diabetes (T2D) is associated with increased cardiovascular disease and mortality. Most diabetes treatments have not proven to reduce this risk and may be associated with worsening of specific cardiovascular risk factors. GLP-1 receptor agonists (GLP-1R agonists) are new incretin-based therapies for the treatment of T2D. They improve glucose control by stimulating insulin secretion and suppressing glucagon release, both in a glucose-dependent manner. There are two GLP-1R agonists approved for the treatment of T2D: once daily liraglutide and twice daily exenatide, both administered by sc injection. Based on recent clinical trials, GLP-1R agonists suggest having a protective role in cardiovascular risk factors besides improving glycemic control, compared to placebo and to standard diabetes therapies. Both liraglutide and exenatide have demonstrated to induce clinically significant weight loss and to reduce systolic blood pressure. Liraglutide also has a positive effect on the lipid profile and cardiovascular risk biomakers. Furthermore, recent data shows a direct effect of GLP-1 and its metabolites in the vascular endothelium and the myocardium, leading to vasodilator effects and improved cardiac function in humans with acute myocardial infarction or congestive heart failure. GLP-1R agonists have a positive impact on cardiovascular risk factors otherwise not addressed by most standard diabetes therapies. Whether these new compounds actually decrease cardiovascular disease and mortality remains to be demonstrated in outcome studies.

Original languageEnglish (US)
Pages (from-to)191-200
Number of pages10
JournalCurrent Diabetes Reviews
Volume6
Issue number4
DOIs
StatePublished - 2010

Fingerprint

Glucagon-Like Peptide 1
Type 2 Diabetes Mellitus
Cardiovascular Diseases
Therapeutics
Blood Pressure
Incretins
Glucose
Mortality
Vascular Endothelium
Glucagon
Vasodilator Agents
Glucagon-Like Peptide-1 Receptor
Weight Loss
Myocardium
Heart Failure
Myocardial Infarction
Placebos
Outcome Assessment (Health Care)
Clinical Trials
Insulin

Keywords

  • Cardiovascular risk
  • Exenatide
  • GLP-1 receptor agonists
  • Incretin
  • Liraglutide
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes. / Verge, Danilo; López, Ximena.

In: Current Diabetes Reviews, Vol. 6, No. 4, 2010, p. 191-200.

Research output: Contribution to journalArticle

@article{8b8c9f7910e54232aafeb0bbcddf7165,
title = "Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes",
abstract = "Type 2 diabetes (T2D) is associated with increased cardiovascular disease and mortality. Most diabetes treatments have not proven to reduce this risk and may be associated with worsening of specific cardiovascular risk factors. GLP-1 receptor agonists (GLP-1R agonists) are new incretin-based therapies for the treatment of T2D. They improve glucose control by stimulating insulin secretion and suppressing glucagon release, both in a glucose-dependent manner. There are two GLP-1R agonists approved for the treatment of T2D: once daily liraglutide and twice daily exenatide, both administered by sc injection. Based on recent clinical trials, GLP-1R agonists suggest having a protective role in cardiovascular risk factors besides improving glycemic control, compared to placebo and to standard diabetes therapies. Both liraglutide and exenatide have demonstrated to induce clinically significant weight loss and to reduce systolic blood pressure. Liraglutide also has a positive effect on the lipid profile and cardiovascular risk biomakers. Furthermore, recent data shows a direct effect of GLP-1 and its metabolites in the vascular endothelium and the myocardium, leading to vasodilator effects and improved cardiac function in humans with acute myocardial infarction or congestive heart failure. GLP-1R agonists have a positive impact on cardiovascular risk factors otherwise not addressed by most standard diabetes therapies. Whether these new compounds actually decrease cardiovascular disease and mortality remains to be demonstrated in outcome studies.",
keywords = "Cardiovascular risk, Exenatide, GLP-1 receptor agonists, Incretin, Liraglutide, Type 2 diabetes",
author = "Danilo Verge and Ximena L{\'o}pez",
year = "2010",
doi = "10.2174/157339910791658853",
language = "English (US)",
volume = "6",
pages = "191--200",
journal = "Current Diabetes Reviews",
issn = "1573-3998",
publisher = "Bentham Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes

AU - Verge, Danilo

AU - López, Ximena

PY - 2010

Y1 - 2010

N2 - Type 2 diabetes (T2D) is associated with increased cardiovascular disease and mortality. Most diabetes treatments have not proven to reduce this risk and may be associated with worsening of specific cardiovascular risk factors. GLP-1 receptor agonists (GLP-1R agonists) are new incretin-based therapies for the treatment of T2D. They improve glucose control by stimulating insulin secretion and suppressing glucagon release, both in a glucose-dependent manner. There are two GLP-1R agonists approved for the treatment of T2D: once daily liraglutide and twice daily exenatide, both administered by sc injection. Based on recent clinical trials, GLP-1R agonists suggest having a protective role in cardiovascular risk factors besides improving glycemic control, compared to placebo and to standard diabetes therapies. Both liraglutide and exenatide have demonstrated to induce clinically significant weight loss and to reduce systolic blood pressure. Liraglutide also has a positive effect on the lipid profile and cardiovascular risk biomakers. Furthermore, recent data shows a direct effect of GLP-1 and its metabolites in the vascular endothelium and the myocardium, leading to vasodilator effects and improved cardiac function in humans with acute myocardial infarction or congestive heart failure. GLP-1R agonists have a positive impact on cardiovascular risk factors otherwise not addressed by most standard diabetes therapies. Whether these new compounds actually decrease cardiovascular disease and mortality remains to be demonstrated in outcome studies.

AB - Type 2 diabetes (T2D) is associated with increased cardiovascular disease and mortality. Most diabetes treatments have not proven to reduce this risk and may be associated with worsening of specific cardiovascular risk factors. GLP-1 receptor agonists (GLP-1R agonists) are new incretin-based therapies for the treatment of T2D. They improve glucose control by stimulating insulin secretion and suppressing glucagon release, both in a glucose-dependent manner. There are two GLP-1R agonists approved for the treatment of T2D: once daily liraglutide and twice daily exenatide, both administered by sc injection. Based on recent clinical trials, GLP-1R agonists suggest having a protective role in cardiovascular risk factors besides improving glycemic control, compared to placebo and to standard diabetes therapies. Both liraglutide and exenatide have demonstrated to induce clinically significant weight loss and to reduce systolic blood pressure. Liraglutide also has a positive effect on the lipid profile and cardiovascular risk biomakers. Furthermore, recent data shows a direct effect of GLP-1 and its metabolites in the vascular endothelium and the myocardium, leading to vasodilator effects and improved cardiac function in humans with acute myocardial infarction or congestive heart failure. GLP-1R agonists have a positive impact on cardiovascular risk factors otherwise not addressed by most standard diabetes therapies. Whether these new compounds actually decrease cardiovascular disease and mortality remains to be demonstrated in outcome studies.

KW - Cardiovascular risk

KW - Exenatide

KW - GLP-1 receptor agonists

KW - Incretin

KW - Liraglutide

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=77954738952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954738952&partnerID=8YFLogxK

U2 - 10.2174/157339910791658853

DO - 10.2174/157339910791658853

M3 - Article

C2 - 20380625

AN - SCOPUS:77954738952

VL - 6

SP - 191

EP - 200

JO - Current Diabetes Reviews

JF - Current Diabetes Reviews

SN - 1573-3998

IS - 4

ER -